The recent publication in the European Respiratory Journal of the proceedings of the 6th World Symposium on Pulmonary Hypertension (WSPH) is an important milestone in pulmonary vascular medicine. Since the first WHO meeting on primary pulmonary hypertension in Geneva in October, 1973, these World Symposia have taken place in Evian (France, 1998) , Venice (Italy, 2003) , Dana Point (USA, 2008) , and twice in Nice (France, 2013, and 2018) . These events have paved the way for better understanding and management of pulmonary hypertension worldwide. In 2018, a group of 124 experts were invited to describe the current state of the art and future directions in pulmonary hypertension. Chapters from 13 task forces have been written by leaders in their respective fields. In this brief overview, we highlight a few novelties from the proceedings.
Previously, pulmonary hypertension with right heart catheterisation was arbitrarily defined as 25 mm Hg mean pulmonary artery pressure (mPAP) or more. However, the upper limit of normal mPAP has been robustly defined to be 20 mm Hg, leaving a diagnostic gap between 21 and 24 mm Hg. It is important to underscore that any value of mPAP above 20 mm Hg defines pulmonary hypertension, which could be explained by different causes with or without pulmonary vascular disease. For example, an elevated pulmonary artery wedge pressure due to left heart disease is a common cause of pulmonary hypertension. In a minority of cases, pre-capillary pulmonary vascular disease will be the cause of elevated mPAP. The 6th WSPH task force definition stated clearly that pre-capillary pulmonary hypertension due to pulmonary vascular disease will be diagnosed when mPAP of over 20 mm Hg is associated with abnormal pulmonary vascular resistance of 3 or more Wood Units. Notably, a change in the haemodynamic definition of pulmonary hypertension due to pulmonary vascular diseases does not imply treating additional patients, but highlights the importance of close monitoring and further research. This is particularly true for patients with known risk factors for a pulmonary vascular disease, such as those with systemic sclerosis or carrying a BMPR2 mutation, or in case of chronic thromboembolism. Another important message from this task force is that elevated mPAP is a biomarker of worse outcomes in different settings, irrespective of the presence of a treatable pulmonary vascular disease. This is the case in the large group of patients with pulmonary hypertension due to left heart disease or chronic lung diseases, in whom the use of drugs approved for pulmonary arterial hypertension (PAH) is not recommended in the absence of positive randomised controlled trials.
Another highlight of the 2018 symposium was a new PAH treatment algorithm. Several medications targeting the endothelin, nitric oxide, and prostacyclin pathways have been approved for PAH in the past 25 years. The most important recent advances in the medical management of PAH have not been related to the discovery of new pathways, but to the development of new strategies for combination therapy and on escalation of treatments based on systematic assessment of clinical response. The new treatment strategy proposed at the 2018 symposium is based on the severity of disease in patients newly diagnosed with PAH, as assessed by a multiparametric risk stratification approach. Clinical, exercise, right ventricular function, and haemodynamic parameters are combined to define a low, intermediate, or high-risk status according to the expected 1-year mortality. The new treatment algorithm provides the most appropriate initial strategy, including monotherapy, or more often initial combination therapy (one or two oral drugs combined with an intravenous prostaglandin in the high-risk population and dual oral combination therapy with an endothelin receptor antagonist and a type 5 phosphodiesterase inhibitor in intermediate-tolow-risk cases). Further treatment escalation is required in case low-risk status is not achieved in planned follow-up assessments. Lung transplantation may be required in most advanced cases on maximal medical therapy.
The symposium also saw developments in the field of chronic thromboembolic pulmonary hypertension (CTEPH). In 1-3% of acute pulmonary embolism cases, abnormal persistent obstruction of proximal or distal pulmonary arteries by residual organised thrombi, combined with a variable microscopic pulmonary vasculopathy indistinguishable from that of PAH, may lead to CTEPH. Lung ventilation/perfusion scintigraphy is the screening test of choice and a normal lung scan rules out CTEPH. In the case of an abnormal perfusion scan, a high-quality pulmonary angiogram is necessary to confirm and define pulmonary vascular involvement. CT pulmonary angiography with or without digital subtraction angiography will characterise vessel morphology for assessment of operability. CTEPH treatment decisions will be made in an expert centre with multidisciplinary teams including experienced surgeons for pulmonary endarterectomy, interventional radiologists and cardiologists, radiologists experienced in pulmonary vascular imaging and pulmonologists and cardiologists with expertise in pulmonary hypertension. MH reports personal fees from Actelion, Merck, and United Therapeutics, and grants and personal fees from Bayer and GlaxoSmithKline (GSK), outside of the submitted work. NG reports grants and personal fees from Actelion, Bayer, GSK, and Pfizer, and personal fees from Merck Sharp & Dohme (MSD) outside of the submitted work. VVMcL reports grants and personal fees from Acceleron, Actelion, Arena, and Bayer, personal fees from Caremark, and United Therapeutics, and grants from Gilead, and Sonovie, outside of the submitted work. LJR reports personal fees from Actelion Pharmaceuticals, SoniVie, Arena Pharmaceuticals, Liquidia Technologies, Bellerophon Pulse Technologies, and Gossamer Bio, outside of the submitted work. GS reports personal fees from Actelion, Bayer, and MSD. Maternal asthma is highly prevalent and is associated with clinically significant perinatal morbidity and mortality. There is an increased risk of small-for-gestational age, preterm birth, neonatal death, and neonatal hospitalisations in pregnancies complicated by asthma. This chronic disease thus represents a substantial health burden for women of reproductive age, affecting the wellbeing and quality of life for both the mother and her offspring.
Uncontrolled maternal asthma during pregnancy has been associated with childhood diseases including childhood wheeze, neurodevelopmental delays, infectious and parasitic diseases, diseases of the respiratory and nervous systems, digestive diseases, skin diseases, endocrine and metabolic disorders, and congenital malformations by age 7 years. However, if maternal asthma is well controlled during pregnancy, then childhood health outcomes are similar to those of children whose mothers are non-asthmatic.
The management of asthma during pregnancy is often a neglected area of clinical care. Antenatal asthma management often requires a multidisciplinary approach, but this approach is limited to women with severe persistent asthma. This level of care needs to be expanded to all pregnant women with asthma to monitor changes in severity of their asthma during pregnancy. There are limited clinical resources for the provision of asthma education during pregnancy, but studies have shown that selfmanagement plans do work well in these clinical settings if supported by a respiratory nurse. There still seems to be a reluctance to administer inhaled corticosteroid treatment and oral steroids during pregnancy to women with asthma. The combination of these factors means the prevalence of asthma-associated adverse outcomes in pregnancies have remained the same from one century to the next, even though numerous studies report substantial improvements in outcomes when asthma is managed effectively during pregnancy. A Cochrane systematic review suggests that the trials done so far are of moderate quality overall, with no firm conclusions about optimal interventions for managing asthma in pregnancy. In view of the limited evidence base, further randomised trials in pregnant women with asthma are required to determine effective and safe interventions. The Managing Asthma in Pregnancy (MAP) trial has made an important contribution to this field by identifying an effective clinical approach for management that showed improvements in maternal asthma control during pregnancy.
The MAP trial was a double-blind, randomised controlled trial in pregnant women with asthma that examined the efficacy of a management algorithm using fractional exhaled nitric oxide (FeNO) as a non-invasive marker of airway inflammation, compared with a group of women who were managed using a symptomsonly approach. Asthma exacerbations in the mother were significantly reduced by 50% in the FeNO group when compared with the symptoms-only management group and indicated that this clinical approach might be effective in controlling asthma in pregnant women, especially for detecting changes in asthma control in women who normally have mild intermittent disease when not pregnant.
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